Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESBA1008 Microvolume Study in Exudative AMD
NCT01849692Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2013
- Primary completion
- Jan 2015
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
A Phase 2 trial of brolucizumab in exudative age-related macular degeneration, sponsored by Alcon Inc.. Started Jun 2013; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01849692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01849692.